← Leaderboards
Michael B Atkins
Beth Israel Deaconess Medical Center
$4,622,469
Attributed
$5,942,444
Total exposure
14
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$23,844,604 · 15
By mechanism
P50$18,901,659 · 5
R01$2,639,950 · 1
U10$1,283,716 · 1
K24$569,679 · 1
P30$443,386 · 1
M01$6,214 · 6
Top collaborators
- Anton Wellstein5 shared
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationHuman SubjectNeoplasm /Cancer ChemotherapyRenal Cell CarcinomaMelanomaInterleukin 2Neoplasm /Cancer ImmunotherapyDrug Screening /EvaluationProgramsRenal CarcinomaClinical TrialsResearch PersonnelInstitutionFundingMalignant NeoplasmsDana-Farber Cancer InstituteAntineoplasticsBaseIntravenous AdministrationAffectCellsMolecularArea
Grant awards (72)
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors$522,708
R01 · FY2022 · CA
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors$533,358
R01 · FY2021 · CA
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors$533,344
R01 · FY2020 · CA
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors$517,329
R01 · FY2019 · CA
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors$533,211
R01 · FY2018 · CA
Kidney Cancer$91,136
P30 · FY2016 · CA · contact PI
Kidney Cancer$91,166
P30 · FY2015 · CA · contact PI
Kidney Cancer$86,357
P30 · FY2014 · CA · contact PI
Developmental Research Program$128,747
P50 · FY2013 · CA · contact PI
Kidney Cancer$83,579
P30 · FY2013 · CA · contact PI
Career Development Program$68,398
P50 · FY2013 · CA · contact PI
Developmental Research Program$134,531
P50 · FY2012 · CA · contact PI
Kidney Cancer$91,148
P30 · FY2012 · CA · contact PI
Career Development Program$67,264
P50 · FY2012 · CA · contact PI
Developmental Research Program$128,245
P50 · FY2011 · CA · contact PI
Eastern Cooperative Oncology Group$95,412
U10 · FY2011 · CA · contact PI
Career Development Program$64,123
P50 · FY2011 · CA · contact PI
DF/HCC Kidney Cancer SPORE$2,300,000
P50 · FY2010 · CA · contact PI
Developmental Research Program$135,596
P50 · FY2010 · CA · contact PI
Eastern Cooperative Oncology Group$104,956
U10 · FY2010 · CA · contact PI
Career Development Program$67,797
P50 · FY2010 · CA · contact PI
DF/HCC Kidney Cancer SPORE$2,300,000
P50 · FY2009 · CA · contact PI
Developmental Research Program$136,532
P50 · FY2009 · CA · contact PI
Eastern Cooperative Oncology Group$130,866
U10 · FY2009 · CA · contact PI
Career Development Program$68,266
P50 · FY2009 · CA · contact PI
DF/HCC Renal Cancer SPORE$1,165,299
P50 · FY2008 · CA · contact PI
Eastern Cooperative Oncology Group$128,678
U10 · FY2008 · CA · contact PI
DF/HCC Renal Cancer SPORE$2,330,598
P50 · FY2007 · CA · contact PI
Eastern Cooperative Oncology Group$128,678
U10 · FY2007 · CA · contact PI
DF/HCC Renal Cancer SPORE$2,400,346
P50 · FY2006 · CA · contact PI
Eastern Cooperative Oncology Group$128,678
U10 · FY2006 · CA · contact PI
Biologic therapy of Melanoma and Renal Cell Cancer$115,395
K24 · FY2006 · CA · contact PI
DF/HCC Renal Cancer SPORE$2,458,254
P50 · FY2005 · CA
Eastern Cooperative Oncology Group$128,678
U10 · FY2005 · CA
Biologic therapy of Melanoma and Renal Cell Cancer$114,918
K24 · FY2005 · CA
DF/HCC Renal Cancer SPORE$2,447,662
P50 · FY2004 · CA
Eastern Cooperative Oncology Group$132,658
U10 · FY2004 · CA
Biologic therapy of Melanoma and Renal Cell Cancer$114,455
K24 · FY2004 · CA
Phase 1 Trial of twice weekly IV IL-12 plus low-dose subcutaneous IL-2$6,214
M01 · FY2004 · RR
DF/HCC Renal Cancer SPORE$2,500,001
P50 · FY2003 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP$152,556
U10 · FY2003 · CA
Biologic therapy of Melanoma and Renal Cell Cancer$113,719
K24 · FY2003 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP$152,556
U10 · FY2002 · CA
Biologic therapy of Melanoma and Renal Cell Cancer$111,192
K24 · FY2002 · CA
IL2 ADMINISTERED BY IV IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA$0
M01 · FY2002 · RR
CORE--CLINICAL DATA MANAGEMENT$0
P50 · FY2002 · CA
CHEMO AND CYTOKINE IMMUNOTHERAPY IN HIGH RISK MELANOMA$0
P50 · FY2002 · CA
TOPICAL TRETINOIN /ORAL FENRETINIDE IN DYSPLASTIC NEVUS$0
M01 · FY2002 · RR
CNI 1493 &IL 2 IN RENAL CELL CARCINOMA &MELANOMA PATIENTS$0
M01 · FY2002 · RR
IVRHIL 12 W/ OR W/OUT TEST DOSE IN PATIENTS W/ ADVANCED MALIGNANCIES$0
M01 · FY2002 · RR
IL2 administered by IV in patients with advanced renal cell carcinoma$0
M01 · FY2002 · RR
IL2 administered by IV in patients with advanced renal cell carcinoma$0
M01 · FY2001 · RR
CHEMO AND CYTOKINE IMMUNOTHERAPY IN HIGH RISK MELANOMA$0
P50 · FY2001 · CA
TOPICAL TRETINOIN /ORAL FENRETINIDE IN DYSPLASTIC NEVUS$0
M01 · FY2001 · RR
CNI 1493 &IL 2 IN RENAL CELL CARCINOMA &MELANOMA PATIENTS$0
M01 · FY2001 · RR
IVRHIL 12 W/ OR W/OUT TEST DOSE IN PATIENTS W/ ADVANCED MALIGNANCIES$0
M01 · FY2001 · RR
IL2 ADMINISTERED BY IV IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA$0
M01 · FY2001 · RR
IL2 ADMINISTERED BY IV IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA$0
M01 · FY2000 · RR
TOPICAL TRETINOIN /ORAL FENRETINIDE IN DYSPLASTIC NEVUS$0
M01 · FY2000 · RR
TOPICAL TRETINOIN /ORAL FENRETINIDE IN DYSPLASTIC NEVUS$0
M01 · FY2000 · RR
TOPICAL TRETINOIN /ORAL FENRETINIDE IN DYSPLASTIC NEVUS$0
M01 · FY2000 · RR
CNI 1493 &IL 2 IN RENAL CELL CARCINOMA &MELANOMA PATIENTS$0
M01 · FY2000 · RR
CNI 1493 &IL 2 IN RENAL CELL CARCINOMA &MELANOMA PATIENTS$0
M01 · FY2000 · RR
CNI 1493 &IL 2 IN RENAL CELL CARCINOMA &MELANOMA PATIENTS$0
M01 · FY2000 · RR
IVRHIL 12 W/ OR W/OUT TEST DOSE IN PATIENTS W/ ADVANCED MALIGNANCIES$0
M01 · FY2000 · RR
IVRHIL 12 W/ OR W/OUT TEST DOSE IN PATIENTS W/ ADVANCED MALIGNANCIES$0
M01 · FY2000 · RR
IVRHIL 12 W/ OR W/OUT TEST DOSE IN PATIENTS W/ ADVANCED MALIGNANCIES$0
M01 · FY2000 · RR
IL2 administered by IV in patients with advanced renal cell carcinoma$0
M01 · FY2000 · RR
IL2 administered by IV in patients with advanced renal cell carcinoma$0
M01 · FY2000 · RR
IL2 administered by IV in patients with advanced renal cell carcinoma$0
M01 · FY2000 · RR
IL2 ADMINISTERED BY IV IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA$0
M01 · FY2000 · RR
IL2 ADMINISTERED BY IV IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA$0
M01 · FY2000 · RR